Author

S. R. Meyer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:imaging· 1 Assay:organoid / primary culture· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

C. J. Zhang· 3 shared J. Z. Sexton· 3 shared M. J. O'Meara· 2 shared R. J. Fontana· 2 shared A. L. Jolly· 1 shared C. E. Wobus· 1 shared C. J. Childs· 1 shared C. Mirabelli· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

C. J. Zhang

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A High-Throughput Microphysiological Liver Chip System to Model Direct and Idiosyncratic Drug-Induced Liver Injury Using Human Liver Organoids

C. J. Zhang, S. R. Meyer, M. A. Garcia, M. C. Procario, S. Yoo, A. L. Jolly, S. Kim, J. Kim, K. Baek, R. D. Kersten, R. J. Fontana, J. Z. Sexton

This paper introduces a high-throughput microfluidic liver chip system using human liver organoids to model drug-induced liver injury with improved sensitivity and prolonged drug exposure capabilities.

bioRxiv · Dec 1, 2023 · PreprintPharmacology & Toxicology

In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment.

J. W. Wotring, S. M. McCarty, K. Shafiq, C. J. Zhang, T. Nguyen, S. R. Meyer, R. Fursmidt, C. Mirabelli, M. C. Clasby, C. E. Wobus, M. J. O'Meara, J. Z. Sexton

This study evaluates niclosamide's limitations as a COVID-19 treatment and identifies analogs with improved potency and reduced toxicity.

bioRxiv · Jun 24, 2022Microbiology

A Human Liver Organoid Screening Platform for DILI Risk Prediction

C. J. Zhang, S. R. Meyer, M. J. O'Meara, S. Huang, M. M. Capeling, D. Ferrer-Torres, C. J. Childs, J. R. Spence, R. J. Fontana, J. Z. Sexton

This study evaluates human liver organoids for DILI risk prediction using high-throughput screening and a liver-on-chip system, showing enhanced predictive capacity and physiological relevance.

bioRxiv · Aug 26, 2021Pharmacology & Toxicology